In participants with highly active disease, the unadjusted annualized relapse rate (ARR) at Week 96 was 0.145 for BRIUMVI versus 0.496 for teriflunomide, representing a 70.8% relative reduction ...

A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most ...

A newly developed MRI-based scoring system may help identify patients at higher risk of early recurrence after surgical removal of small hepatocellular carcinoma (HCC). The findings, published in ...

Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablationFindings may impact treatment guidelines issued by ...

IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...

IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical study ...

Campylobacter hepaticus is the causative agent of spotty liver disease, resulting in mortality and production loss in laying hens. The disease is primarily associated with free range laying birds and ...

New research from a University of Cincinnati Cancer Center study found external beam radiation therapy (EBRT) is safe to ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

Marisa Garshick, MD, FAAD, is a board-certified dermatologist and clinical assistant professor of dermatology. Skin lesions can be primary (present from birth or develop later in life) or secondary ...